PFE240927P29500
- 0.37
- -0.18-32.73%
Pfizer Newsroom
pfizer globally recalls Oxbryta, a sickle cell disease treatment drug, due to increased risks of complications and death.
According to Reuters on September 26, USA pharmaceutical company pfizer announced on Wednesday that it will withdraw its sickle cell disease treatment drug Oxbryta from all approved markets, citing increased risks of complications and death associated with the drug. Pfizer acquired Oxbryta when it bought Global Blood Therapeutics for 5.4 billion dollars in 2022. The company reported that the therapy generated revenue of 0.328 billion dollars in 2023. The drug withdrawal occurred as the European Medicines Agency's Committee for Medicinal Products for Human Use held a "special meeting" to review pfizer's drugs beforehand. In a study of 2
Express News | Pfizer and ShangPharma Group reached a strategic cooperation.
Agios Cut at Leerink on Overhang From Pfizer's Oxbryta Withdrawal
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Cuts Target Price to $33
Jefferies Remains a Buy on Pfizer (PFE)
Express News | Pfizer : Jefferies Cuts Target Price to $33 From $35
Pfizer (PFE) Rises But Trails Market: What Investors Should Know
Pfizer Options Spot-On: On September 26th, 107.56K Contracts Were Traded, With 2.77 Million Open Interest
On September 26th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 107.56K options for the day, of which put options accounted for 33.53% of the total transactions,
Express News | FDA: Patients and Caregivers Should Contact Their Health Care Professional About Stopping Oxbryta and Starting Another Treatment Option
Express News | FDA Is Alerting Patients and Health Care Professionals About Voluntary Withdrawal of Oxbryta From Market Due to Safety Concerns
Fulcrum Therapeutics Swings up 17% on Pfizer Sickle Cell Drug Setback
Fulcrum Therapeutics Potential Winner After Pfizer Pulls Oxbryta -- Market Talk
Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com
Pfizer's Oxbryta Exit May Hasten Trials of Rival Experimental Sickle Cell Drugs, Analysts Say
Time to Order Your Free At-Home Covid Tests. Here's How. -- Barrons.com
EU Regulator Recommends Suspension of Pfizer's Sickle Cell Disease Treatment
Express News | EMA: Chmp Considered That Data From Ongoing EMA Review Raise Serious Concerns About Safety of Oxbryta Due to Increased Uncertainties
Express News | EMA Recommends Suspension of Sickle Cell Disease Medicine Oxbryta
Pfizer Recalls All of Its Sickle Cell Disease Treatment Over Safety Concerns
Pfizer Voluntarily Withdraws Sickle Cell Disease Treatment Oxbryta From Global Market Due To Painful Disease Complication, Deaths